ADMA BIOLOGICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
ADMA BIOLOGICS, INC. (ADMA) reported Increase (Decrease) in Prepaid Expense and Other Assets of $1.18 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-05
- ADMA BIOLOGICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$420.00K.
- ADMA BIOLOGICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $1.60M, a 38.33% decline year-over-year.
- ADMA BIOLOGICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $547.00K.
- ADMA BIOLOGICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$1.12M, a 127.78% decline year-over-year.
- ADMA BIOLOGICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.52M, a 43.41% decline from fiscal 2024.
- ADMA BIOLOGICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $2.69M, a 1027.62% increase from fiscal 2023.
- ADMA BIOLOGICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $239.00K, a 68.39% decline from fiscal 2022.
- ADMA BIOLOGICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $756.00K, a 41.53% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 3 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$420.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $1.18M 10-Q · filed 2026-08-05 | $1.73M derived: sum of 3 quarters · filed 2026-08-05 | $611.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $1.60M 10-Q · filed 2026-05-06 | $2.15M derived: sum of 2 quarters · filed 2026-05-06 | $1.03M derived: sum of 3 quarters · filed 2026-05-06 | $530.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $547.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$570.00K derived: sum of 2 quarters · filed 2026-02-25 | -$1.07M derived: sum of 3 quarters · filed 2026-08-05 | $1.52M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.62M derived: sum of 2 quarters · filed 2026-08-05 | $978.00K 10-Q · filed 2025-11-05 | -$538.00K derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | -$501.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $2.10M 10-Q · filed 2026-08-05 | $579.00K derived: sum of 3 quarters · filed 2026-08-05 | $4.60M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $2.60M 10-Q · filed 2026-05-06 | $1.08M derived: sum of 2 quarters · filed 2026-05-06 | $5.10M derived: sum of 3 quarters · filed 2026-05-06 | $6.88M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.50M derived: sum of 2 quarters · filed 2026-02-25 | $4.29M derived: sum of 3 quarters · filed 2026-02-25 | $2.69M 10-K · filed 2026-02-25 | ||||
| 2024-09-30 | $4.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.80M derived: sum of 2 quarters · filed 2025-11-05 | $4.21M 10-Q · filed 2025-11-05 | $4.44M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $1.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $190.00K 10-Q · filed 2025-08-06 | $417.00K derived: sum of 3 quarters · filed 2026-02-25 | $305.00K derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | -$1.59M 10-Q · filed 2025-05-07 | -$1.37M derived: sum of 2 quarters · filed 2026-02-25 | -$1.48M derived: sum of 3 quarters · filed 2026-02-25 | -$638.00K derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | $227.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $115.00K derived: sum of 2 quarters · filed 2026-02-25 | $955.00K derived: sum of 3 quarters · filed 2026-02-25 | $239.00K 10-K · filed 2026-02-25 | ||||
| 2023-09-30 | -$112.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $728.00K derived: sum of 2 quarters · filed 2024-11-07 | $12.00K 10-Q · filed 2024-11-07 | $12.31K 10-Q · filed 2023-11-08 | -$265.24K derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-06-30 | $840.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $124.00K 10-Q · filed 2024-08-08 | $123.59K 10-Q · filed 2023-08-09 | -$153.24K derived: sum of 3 quarters · filed 2025-03-18 | -$180.68K derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2023-03-31 | -$716.00K 10-Q · filed 2024-05-09 | -$716.47K 10-Q · filed 2023-05-10 | -$993.24K derived: sum of 2 quarters · filed 2025-03-18 | -$1.02M derived: sum of 3 quarters · filed 2025-03-18 | -$1.14M derived: sum of 4 quarters · filed 2025-03-18 | |||
| 2022-12-31 | -$277.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$304.68K derived: sum of 2 quarters · filed 2025-03-18 | -$424.06K derived: sum of 3 quarters · filed 2025-03-18 | $756.00K 10-K · filed 2025-03-18 | $755.90K 10-K · filed 2023-03-23 | |||
| 2022-09-30 | -$27.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$146.82K derived: sum of 2 quarters · filed 2023-11-08 | $1.03M 10-Q · filed 2023-11-08 | -$486.34K derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-06-30 | -$119.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $1.06M 10-Q · filed 2023-08-09 | -$458.90K derived: sum of 3 quarters · filed 2024-02-28 | -$301.71K derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2022-03-31 | $1.18M 10-Q · filed 2023-05-10 | -$339.52K derived: sum of 2 quarters · filed 2024-02-28 | -$182.34K derived: sum of 3 quarters · filed 2024-02-28 | -$283.09K derived: sum of 4 quarters · filed 2024-02-28 | ||||
| 2021-12-31 | -$1.52M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$1.36M derived: sum of 2 quarters · filed 2024-02-28 | -$1.46M derived: sum of 3 quarters · filed 2024-02-28 | $1.29M 10-K · filed 2024-02-28 | $1.29M 10-K · filed 2022-03-24 | |||
| 2021-09-30 | $157.18K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $56.44K derived: sum of 2 quarters · filed 2022-11-09 | $2.81M 10-Q · filed 2022-11-09 | $2.07M derived: sum of 4 quarters · filed 2022-11-09 | ||||
| 2021-06-30 | -$100.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $2.66M 10-Q · filed 2022-08-10 | $1.92M derived: sum of 3 quarters · filed 2022-08-10 | $1.01M derived: sum of 4 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | $2.76M 10-Q · filed 2022-05-11 | $2.02M derived: sum of 2 quarters · filed 2022-05-11 | $1.11M derived: sum of 3 quarters · filed 2022-05-11 | |||||
| 2020-12-31 | -$739.96K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$1.65M derived: sum of 2 quarters · filed 2022-03-24 | $512.87K 10-K · filed 2022-03-24 | |||||
| 2020-09-30 | -$907.01K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.25M 10-Q · filed 2021-11-10 | ||||||
| 2020-06-30 | $2.16M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |